These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 28992764)
1. Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective. Cantú-Brito C; Silva GS; Ameriso SF Clin Appl Thromb Hemost; 2018 Jan; 24(1):22-32. PubMed ID: 28992764 [TBL] [Abstract][Full Text] [Related]
2. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions. Cheng JW; Barillari G J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983 [TBL] [Abstract][Full Text] [Related]
3. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
4. [Consensus statement: Management of oral anticoagulation for stroke prevention in patients with nonvalvular atrial fibrillation]. Helms TM; Silber S; Schäfer A; Masuhr F; Palm F; Darius H; Schrör K; Bänsch D; Bramlage P; Hankowitz J; Karle CA; Stargardt T; Weil J; Geller JC Herzschrittmacherther Elektrophysiol; 2016 Sep; 27(3):295-306. PubMed ID: 27576696 [TBL] [Abstract][Full Text] [Related]
5. The role of rivaroxaban in atrial fibrillation and acute coronary syndromes. Reddy P; Giugliano RP J Cardiovasc Pharmacol Ther; 2014 Nov; 19(6):526-32. PubMed ID: 24659084 [TBL] [Abstract][Full Text] [Related]
6. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. Alcocer L Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792 [TBL] [Abstract][Full Text] [Related]
7. Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. Kalabalik J; Rattinger GB; Sullivan J; Slugocki M; Carbone A; Rivkin A Drugs; 2015 Jun; 75(9):979-98. PubMed ID: 25998374 [TBL] [Abstract][Full Text] [Related]
8. Benefits and risks of oral anticoagulation for stroke prevention in nonvalvular atrial fibrillation. Garcia DA Thromb Res; 2012 Jan; 129(1):9-16. PubMed ID: 22018997 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation. Senoo K; Lip GY Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085 [TBL] [Abstract][Full Text] [Related]
10. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K; Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811 [TBL] [Abstract][Full Text] [Related]
11. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation. Deitelzweig S Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252 [TBL] [Abstract][Full Text] [Related]
12. New anticoagulants (dabigatran, apixaban, rivaroxaban) for stroke prevention in atrial fibrillation. Aguilar MI; Kuo RS; Freeman WD Neurol Clin; 2013 Aug; 31(3):659-75. PubMed ID: 23896498 [TBL] [Abstract][Full Text] [Related]
13. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related]
16. Practical Considerations for the Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation. Stacy Z; Richter S Clin Appl Thromb Hemost; 2017 Jan; 23(1):5-19. PubMed ID: 26988835 [TBL] [Abstract][Full Text] [Related]
17. Prevention of stroke in patients with atrial fibrillation. Olsson SB; Halperin JL Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916 [TBL] [Abstract][Full Text] [Related]
18. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284 [TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Janzic A; Kos M Pharmacoeconomics; 2015 Apr; 33(4):395-408. PubMed ID: 25512096 [TBL] [Abstract][Full Text] [Related]